Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach.

Theranostic metabolic and molecular probes have been successfully applied to predict and monitor response to radionuclide-based therapies. In particular, both Tc-MDP and F-NaF resulted useful tools for personalized dosimetry and prognostic stratification before Ra-therapy, while PSMA-ligands, alone or in combination with F-FDG, provided valuable information to select patients who are more likely to benefit from RLT and getting information on PCa grade of differentiation and aggressiveness. In spite of its high potential, PET-radiomics for PCa is still at an embryonic phase and needs further validation.